Nano-sized drug particle NSAIDs could be effective in the management of pain and warrant further evaluation, according a presentation at PAINWeek 2012.
An orally inhaled dihydroergotamine studied for the rescue treatment of acute migraine exhibited significant pain relief compared with placebo, according to the results of a pivotal phase 3 trial presented at PAINWeek 2012
An analysis of tapentadol immediate-release showed it may offer an effective pain management option for post-operative hospitalized patients, as reported at PAINWeek 2012.
Fentanyl buccal tablets have been shown to provide a more rapid onset of analgesia than immediate-release oxycodone for the relief of breakthrough back pain, as reported at PAINWeek 2012.
Larry Dillaha, MD, of INSYS Therapeutics, Phoenix, AZ, and colleagues reported at PAINWeek 2012 that fentanyl sublingual spray markedly improved satisfaction with symptom relief among patients with breakthrough cancer pain (BTCP).
Tapentadol extended-release tablets is efficacious in the management of moderate-to-severe chronic pain associated with diabetic peripheral neuropathy in adults, according study results presented at PAINWeek 2012.
When used in combination with pregabalin and gabapentin, lidocaine 5% patch is well tolerated and safe for postherpetic neuralgia (PHN), according to a presentation at PAINWeek 2012.
Lidocaine patch 5% is effective and well-tolerated if applied to the face, trunk, or extremities, according to the results of a study in patients with postherpetic neuralgia reported during PAINWeek 2012.
Patients with chronic neuropathic pain can be safely and effectively converted and maintained on hydromorphone extended-release, as shown in a study presented at PAINWeek 2012.
Charles E. Argoff, MD, from Albany (NY) Medical Center, discussed diabetic peripheral neuropathy, at PAINWeek 2012, including how to recognize and treat this often undiagnosed condition.
In a plenary session at PAINWeek 2012, three mental health experts described innovative programs that have been developed to help improve care for patients with chronic pain and psychiatric comorbidities.
A combination of ibuprofen plus a high-dose H2-receptor antagonist such as famotidine may decrease ibuprofen-induced ulcer disease, according to a study presented at PAINWeek 2012.
LAS VEGAS, NV—A meta-analysis presented at PAINWeek 2012 of two OTC doses of ibuprofen showed that 400 mg provided significantly better overall pain relief compared with 200 mg over a 6-hour period.
Theramine, a prescription-only amino acid food product, may offer a safe alternative to traditional pharmaceutical products used to treat chronic back pain, according to a presentation at PAINWeek 2012.
Oral methylnaltrexone is generally safe and well tolerated in patients with chronic, non-cancer pain and opioid-induced constipation, according to results of a study presented at PAINWeek 2012.